摘要
目的 通过观察氯吡格雷对急性冠脉综合征患者炎症因子的影响，探讨氯吡格雷除抑制血小板聚集作用之外的抗炎作用。方法 急性冠脉综合征患者89例，随机分组为A组（n=44，阿司匹林组），B组（n=45，阿司匹林＋氯吡格雷组），另选c组（n=25，健康对照组）。分别在用药前、用药后第10、30天抽取空腹静脉血，检测高敏C反应蛋白（hs—CRP）。观察用药后30d主要不良事件（MACE）的发生情况。结果用药前A，B两组患者血清hs—CRP明显高于c组。用药后10d，AB两组病人血清hs—CRP降低。用药后30d，AB两组病人血清hs—CRP进一步降低，且B组较A组下降更显著（P〈0．05）。AB两组MACE发生情况差异有统计学意义（P〈0．05），尤其心绞痛发作B组明显低于A组（P〈0．01）。结论 氯吡格雷对于急性冠脉综合征患者除抑制血小板聚集作用外，还具有独立的抗炎作用，可显著减轻动脉炎症反应，抑制动脉粥样硬化的进展，改善患者预后。
Objective To observe the change of serum high sensitivity C - reactive protein （hs - CRP） level in patients with acute coronary syndrome （ACS）when clopidogrel is used comparing it with the reference. Methods Eighty -nine patients with ACS were randomily divided into two groups. Group A （aspirin alone, n =44） and group B （aspirin plus clopidogrel, n =45）, 25 healthy volunteers were treated as normal control group （group C ）. Serum high sensitivity C - reactive protein （hs - CRP） were measured in all patients at baseline prior to any drug treatment after admission,and at 10 and 30 days after beginning drug treatment. The major adverse cardiovascular events （MACE）were evaluated for 30 days after taking medicine. Results Before taking medicine, the concentrations of hs - CRP in both group A and group B were significantly higher than those in group C. 10 days after taking medicine, the concentrations of hs - CRP in both group A and group B decreased significantly 30 dags. After taking medicine, the concentrations of hs - CRP in both group A and group B decreased significantly, Compared with group A, the concentrations of hs - CRP in group B decreased significantly （ P 〈 0.05 ） , and significantly lower levels of hs - CRP observed in group B compared with Group A at 30 days after initiating drug. Conclusion In addition to suppress platelet adhesion, elopidogrel has anti - inflammation effect and restrain the development of atheroselerosis in patients with ACS. Accordingly, it improves the prognosis of ACS patients.
出处
《中原医刊》
2007年第15期22-23,共2页
Central Plains Medical Journal
关键词
氯吡格雷
急性冠脉综合征
炎症
高敏C反应蛋白
Clopidogrel
Acute coronary syndrome
Inflammation
High sensitivity C - reactive protein
